Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CPS1 | P31327 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113759 | 0.93 | MAPT (0.61) | MAPTLMNAKDM4EALDH1A1HTT | |
| SCHEMBL4115692 | 0.93 | KDM2B (0.47) | MAPTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4126643 | 0.86 | NPC1 (0.53) | MAPTLMNAKDM4EALDH1A1HTT | |
| SCHEMBL4133619 | 0.86 | MAPT (0.66) | MAPTLMNAKDM4EALDH1A1HTT | |
| SCHEMBL11214722 | 0.81 | ALDH1A1 (0.49) | MAPTLMNAKDM4EALDH1A1HTT | |
| SCHEMBL30785090 | 0.80 | KDM4E (0.55) | MAPTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9820804 | 0.80 | KDM4E (0.55) | MAPTLMNAKDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL10640715 | 0.80 | ALDH1A1 (0.48) | MAPTLMNAKDM4EALDH1A1HTT | |
| SCHEMBL16163091 | 0.78 | POLB (0.61) | MAPTLMNAKDM4EALDH1A1KDM2B | |
| SCHEMBL1942608 | 0.78 | CPS1 (0.70) | KDM2BCPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | CYP1A1, PRDX1, CYP1A2 | MAPT 3870/4885LMNA 2761/4885KDM4E 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.